ABL Bio
ABL Bio Inc is a South Korean clinical-stage biotechnology company focused on developing bispecific antibody therapeutics for oncology and neurodegenerative diseases. The company utilizes its proprietary Grabody platform to engineer targeted antibody candidates that cross the blood-brain barrier and target immune checkpoints. Revenue is generated from research collaboration milestone payments, upfront licensing option fees, and R&D support contracts with global biopharmaceutical partners. Core end markets serve oncology patients, neurodegenerative disease centers, and global pharmaceutical drug development divisions. ABL Bio holds a pioneering position in South Korea's biopharmaceutical sector for bispecific antibody engineering and brain delivery technologies. The company is headquartered in Seongnam, South Korea, and its common shares trade on the KOSDAQ market of the Korea Exchange.
4 of the funds FundTelligence covers report a position in ABL Bio.
- Legal name
- ABL Bio Inc
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 4
Funds holding ABL Bio
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.11 % (full portfolio disclosed, October 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)